Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PYXS
stocks logo

PYXS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.325
+23.95%
--
--
-0.323
-7.62%
--
--
-0.323
+7.78%
Estimates Revision
The market is revising Upward the revenue expectations for Pyxis Oncology, Inc. (PYXS) for FY2025, with the revenue forecasts being adjusted by 1.18% over the past three months. During the same period, the stock price has changed by 126.18%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.18%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.1%
In Past 3 Month
Stock Price
Go Up
up Image
+126.18%
In Past 3 Month
Wall Street analysts forecast PYXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYXS is 7.07 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast PYXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYXS is 7.07 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.320
sliders
Low
5.00
Averages
7.07
High
9.00
Current: 4.320
sliders
Low
5.00
Averages
7.07
High
9.00
Stephens
Loganathan
Overweight
maintain
$5 -> $8
2025-11-24
Reason
Stephens
Loganathan
Price Target
$5 -> $8
2025-11-24
maintain
Overweight
Reason
Stephens analyst Sudan Loganathan raised the firm's price target on Pyxis Oncology to $8 from $5 and keeps an Overweight rating on the shares, citing "growing conviction" around MICVO and its potential to be a competitive treatment option for recurrent or metastatic head and neck squamous cell carcinoma.
Stifel
Stephen Willey
Buy
initiated
$9
2025-11-03
Reason
Stifel
Stephen Willey
Price Target
$9
2025-11-03
initiated
Buy
Reason
Stifel analyst Stephen Willey resumed coverage of Pyxis Oncology with a Buy rating and $9 price target. The firm believes micvotabart pelidotin is "a convention-defying ADC intentionally designed to better-optimize what Enhertu achieves serendipitously" and believes Phase 1 dose-escalation data establishes clear mechanistic proof-of-concept, the analyst tells investors. The firm sees year-end disclosure of preliminary MICVO data supporting a registration-directed effort as a second-line and later SCCHN agent in a competitively-nascent, soon-to-be multi-billion-dollar total addressable market, the analyst added.
Guggenheim
Buy
initiated
$5
2025-09-04
Reason
Guggenheim
Price Target
$5
2025-09-04
initiated
Buy
Reason
Guggenheim initiated coverage of Pyxis Oncology with a Buy rating and $5 price target. The firm believes the market may incorrectly written off micvotabart pelidotin, a first-in-concept non-internalizing antibody-drug conjugate against the novel target extra-domain B splice variant of fibronectin in the tumor stroma. The analyst thinks Pyxis may have a viable development path for micvotabart.
Guggenheim
Buy
initiated
$5
2025-09-03
Reason
Guggenheim
Price Target
$5
2025-09-03
initiated
Buy
Reason
Guggenheim initiated coverage of Pyxis Oncology with a Buy rating and $5 price target.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$5
2025-03-19
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$5
2025-03-19
Reiterates
Strong Buy
Reason
RBC Capital
Leonid Timashev
Buy
Reiterates
$8
2025-03-19
Reason
RBC Capital
Leonid Timashev
Price Target
$8
2025-03-19
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pyxis Oncology Inc (PYXS.O) is -3.53, compared to its 5-year average forward P/E of -1.92. For a more detailed relative valuation and DCF analysis to assess Pyxis Oncology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.92
Current PE
-3.53
Overvalued PE
-0.36
Undervalued PE
-3.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.42
Undervalued EV/EBITDA
-1.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
68.06
Current PS
0.00
Overvalued PS
219.97
Undervalued PS
-83.86
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PYXS News & Events

Events Timeline

(ET)
2025-11-03
07:05:30
Pyxis Oncology announces Q3 earnings per share of 35 cents, surpassing consensus estimate of 34 cents.
select
2025-10-09 (ET)
2025-10-09
07:33:23
Pyxis Oncology names Alex Kane as Senior Vice President of Investor Relations and Capital Markets
select
2025-08-14 (ET)
2025-08-14
16:13:00
Pyxis Oncology reports Q2 EPS (30c), consensus (35c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-14Newsfilter
Pyxis Oncology to Showcase Translational Data and Important Biological Insights on MICVO's Mechanism of Action at Upcoming Medical Conferences

  • Overview of MICVO: Pyxis Oncology is set to present translational data for micvotabart pelidotin (MICVO), an innovative antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin, at ESMO 2025 and AACR-NCI-EORTC conferences, showcasing its unique mechanism of action against solid tumors.

  • Mechanism of Action: MICVO operates through a three-pronged approach: direct tumor cell killing, bystander effect, and immunogenic cell death, while also remodeling the tumor microenvironment and activating immune responses, particularly in head and neck squamous cell carcinoma (HNSCC).

[object Object]
Preview
5.0
10-09Newsfilter
Pyxis Oncology Names Alex Kane as Senior Vice President of Investor Relations and Capital Markets

  • New Appointment: Pyxis Oncology has appointed Alex Kane as Senior Vice President of Investor Relations & Capital Markets, effective immediately, bringing 20 years of experience in the life sciences sector.

  • Professional Background: Kane previously worked at Guggenheim Securities and held senior roles at Praxis Precision Medicines and PTC Therapeutics, focusing on investor relations and capital markets strategies.

  • Company Focus: Pyxis Oncology is dedicated to developing antibody-drug conjugate therapeutics for challenging cancers, with its lead candidate, MICVO, currently in Phase 1 clinical studies targeting recurrent and metastatic head and neck squamous cell carcinoma.

  • Strategic Importance: The company emphasizes Kane's expertise in communicating value-creation opportunities, which will be vital as they advance their clinical programs and prepare for future milestones.

[object Object]
Preview
5.0
07-01Newsfilter
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Stock Options Granted: Pyxis Oncology, Inc. announced the granting of stock options to purchase 246,238 shares of common stock to four new employees as part of their 2022 Inducement Plan, with vesting schedules and an exercise price of $1.10.

  • Company Focus: The company is dedicated to developing next-generation antibody-drug conjugates for challenging cancers, with ongoing clinical studies for its lead candidate targeting recurrent and metastatic head and neck squamous cell carcinoma.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pyxis Oncology Inc (PYXS) stock price today?

The current price of PYXS is 4.32 USD — it has decreased -6.09 % in the last trading day.

arrow icon

What is Pyxis Oncology Inc (PYXS)'s business?

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

arrow icon

What is the price predicton of PYXS Stock?

Wall Street analysts forecast PYXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYXS is 7.07 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pyxis Oncology Inc (PYXS)'s revenue for the last quarter?

Pyxis Oncology Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Pyxis Oncology Inc (PYXS)'s earnings per share (EPS) for the last quarter?

Pyxis Oncology Inc. EPS for the last quarter amounts to -0.35 USD, decreased -0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pyxis Oncology Inc (PYXS)'s fundamentals?

The market is revising Upward the revenue expectations for Pyxis Oncology, Inc. (PYXS) for FY2025, with the revenue forecasts being adjusted by 1.18% over the past three months. During the same period, the stock price has changed by 126.18%.
arrow icon

How many employees does Pyxis Oncology Inc (PYXS). have?

Pyxis Oncology Inc (PYXS) has 44 emplpoyees as of December 05 2025.

arrow icon

What is Pyxis Oncology Inc (PYXS) market cap?

Today PYXS has the market capitalization of 268.98M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free